Conference Coverage

General views from the 2019 Annual Meeting of the American Society (ASCO), held May 31 - June 4, 2019. Courtesy © ASCO/Phil McCarten 2019.

RC48-ADC Demonstrates Clinically Meaningful Results in HER2+ Metastatic and Unresectable Urothelial Cancer

Clinically meaningful topline results for a Phase II clinical trial of RC48-ADC were presented during the annual meeting of...
General Views of the 55th Annual Meeting meeting of the American Society of Clinical Oncology. Photo Courtesy: © ASCO/Nick Agro 2019.

Preliminary Phase I Data for U3-1402 Shows Manageable Safety and Reduction in Tumor Size...

Preliminary results from the dose escalation part of the phase I study with U3-1402, an investigational and potential first-in-class...
Exhibition booth Seattle Genetics - ASCO 2019 | Courtsey: Emila Duaerte / Sunvalley Communication

Phase III Clinical Trials of Brentuximab Vedotin Continue to Demonstrate Superior Clinical Activity

Additional, updated, analyses of results from ECHELON-1 and ECHELON-2, the frontline phase III trials of brentuximab vedotin (Adcetris®; Seattle...
Astellas Pharma, Exhibition booth during ASCO 2019, held May 31 – June 4, 2019 in Chicago, Ill.| Courtsey: Emila Duaerte / Sunvalley Communication

Enfortumab Vedotin Produces High Tumor Response in Metastatic Urothelial Cancer

Enfortumab vedotin (also known as ASG-22CE), an investigational antibody-drug conjugates being developed by Seattle Genetics in collaboration with Astellas...

Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 ASCO Annual Meeting

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates or ADCs targeting...
Daiichi Sankyo

Daiichi Sankyo to Present ADC Pipeline Results

Data for several investigational compounds in the Daiichi Sankyo oncology pipeline will be presented at the upcoming annual meeting...

ASCO 2019 ADC Presentation Guide

We have created the following guide to all presentations related to ADCs for the upcoming ASCO Annual Meeting 2019...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

Phase I Data for SAR408701 Supports Further Development in Lung Cancer

During the upcoming annual meeting American Society of Clinical Oncology (ASCO) in June 2019, Sanofi's oncology franchise will present...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers

Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called...
The sign I Amsterdam in front of rijksmuseum in Amsterdam, The Netherlands.

Sutro Presents Preliminary Results From Ongoing Phase I Study of STRO-001

California-based Sutro Biopharma has confirmed that the company will present preliminary results from the first 14 patients enrolled in...

FEATURED RESOURCES